Primary Subretinal Seeding in Retinoblastoma: Clinical Presentation and Treatment Outcomes.
Chemotherapy
Ophthalmic oncology
Retinoblastoma
Subretinal seeding
Treatment
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
17
01
2023
accepted:
23
03
2023
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
20
2
2024
Statut:
ppublish
Résumé
The aim of this study was to describe the clinical features and treatment outcomes of primary subretinal seeding (SRS) in patients with intraocular retinoblastoma (RB). Descriptive analysis of primary SRS in 47 patients (50 eyes) with RB was performed. Mean age was 19 months (range, 2-72 months), and 55% ( Primary SRS pose a therapeutic challenge during RB treatment. The SRS responds moderately to systemic IVC, with one-third cases showing SRS recurrence and one-fifth ultimately requiring enucleation.
Identifiants
pubmed: 38376084
doi: 10.1159/000530497
pii: 530497
pmc: PMC10821785
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32-39Informations de copyright
© 2023 S. Karger AG, Basel.
Déclaration de conflit d'intérêts
There are any no competing financial interests in relation to the work described in this manuscript.